Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Bibliographic Details
Title: Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
Authors: Corre, Jill 1, ∗, Vincent, Laure 2, Moreau, Philippe 3, Hebraud, Benjamin 4, Hulin, Cyrille 5, Béné, Marie-Christine 6, Broijl, Annemiek 7, Caillot, Denis 8, Delforge, Michel 9, Dejoie, Thomas 10, Facon, Thierry 11, Lambert, Jérôme 12, Leleu, Xavier 13, Macro, Margaret 14, Perrot, Aurore 4, Zweegman, Sonja 15, Filleron, Thomas 16, Cabarrou, Bastien 16, van de Donk, Niels W. C. J. 15, Mahéo, Sabrina 1, Hua, Winnie 17, Wang, Jianping 18, Krevvata, Maria 18, Vanquickelberghe, Véronique 19, de Boer, Carla 20, Tuozzo, Alba 18, Borgsten, Fredrik 21, Rowe, Melissa 22, Carson, Robin 18, Wuilleme, Soraya 6, Sonneveld, Pieter 7
Source: In Blood March 2025
Database: ScienceDirect
More Details
ISSN:00064971
DOI:10.1182/blood.2024027620
Published in:Blood
Language:English